Yes, ARA-290 has been investigated in multiple Phase 2 clinical trials, including studies in sarcoidosis-associated neuropathy and metabolic parameters in type 2 diabetes
We've compiled a short list of the most common pitfalls researchers encounter
This is especially crucial for patients with neurological symptoms, which can easily become permanent if under-treated long enough
Gojkovic, S., Krezic, I., Kasnik Kovac, K., Malekinusic, D., Vrdoljak, B., & Kolovrat, M
When Eli Lilly and Novo throw out a $7 billion number, where they're cooking the books is they're not telling legislators that a lot of that is gray and black market, 4 out of 5, meaning there is no clinician in the chain of custody